A Randomized Controlled Trial of Ganaxolone in Posttraumatic Stress Disorder

Total Page:16

File Type:pdf, Size:1020Kb

A Randomized Controlled Trial of Ganaxolone in Posttraumatic Stress Disorder Psychopharmacology (2017) 234:2245–2257 DOI 10.1007/s00213-017-4649-y ORIGINAL INVESTIGATION A randomized controlled trial of ganaxolone in posttraumatic stress disorder Ann M. Rasmusson1,2 & Christine E. Marx3 & Sonia Jain4 & Gail M. Farfel5,6 & Julia Tsai5 & Xiaoying Sun4 & Thomas D. Geracioti7 & Mark B. Hamner8 & James Lohr4,9 & Richard Rosse10 & Lanier Summerall11 & Jennifer C. Naylor3 & Cristine Cusin12,13 & Ariel J. Lang4,9 & Rema Raman14 & Murray B. Stein4,9 Received: 14 December 2016 /Accepted: 13 May 2017 /Published online: 1 July 2017 # Springer-Verlag Berlin Heidelberg (outside the USA) 2017 Abstract Preclinical and clinical research supports a role for repeated measures analysis revealed no significant differences neuroactive steroids in the pathophysiology of posttraumatic between the effects of ganaxolone and placebo on Clinician stress disorder (PTSD). We investigated ganaxolone (a syn- Administered PTSD Symptom (CAPS) scores, global well- thetic 3β-methylated derivative of allopregnanolone, a being, negative mood, or sleep. Dropout rates did not differ GABAergic neuroactive steroid) for treatment of PTSD in a between groups, and ganaxolone was generally well tolerated. proof-of-concept, multisite, double-blind, placebo-controlled Trough blood levels of ganaxolone at the end of the double- trial. Veteran and non-veteran participants (n = 112) were ran- blind phase were, however, lower than the anticipated thera- domized to ganaxolone or placebo at biweekly escalating peutic level of ganaxolone in >35% of participants on active doses of 200, 400, and 600 mg twice daily for 6 weeks. drug. Pharmacokinetic profiling of the ganaxolone dose regi- During an open-label 6-week extension phase, the initial men used in the trial and adverse event sensitivity analyses ganaxolone group continued ganaxolone, while the placebo suggest that under-dosing may have contributed to the failure group crossed over to ganaxolone. Eighty-six and 59 partici- of ganaxolone to out-perform placebo. Future investigations pants, respectively, completed the placebo-controlled and of ganaxolone may benefit from higher dosing, rigorous mon- open-label phases. A modified intent-to-treat mixed model itoring of dosing adherence, a longer length of placebo- Ann M. Rasmusson and Christine E. Marx share first authorship and are the lead investigators responsible for the design and implementation of the study as submitted for funding and support to the INTRuST Clinical Consortium Coordinating Center. * Ann M. Rasmusson 7 VA Medical Center Cincinnati and University of Cincinnati College ann.rasmusson@va.gov of Medicine, Cincinnati, OH, USA 8 Ralph H. Johnson VA Medical Center and Medical University of 1 National Center for PTSD-Women’s Health Science Division, South Carolina, Charleston, SC, USA Department of Veterans Affairs, Boston University School of 9 VA San Diego Healthcare System, San Diego, CA, USA Medicine, Boston, MA, USA 10 2 VA Boston Healthcare Center, (116B-3), 150 South Huntington Washington DC VA Medical Center, Washington, DC, USA Avenue, Boston, MA 02130, USA 11 Manchester VA Medical Center and White River Junction VA 3 Durham VA Medical Center, VA Mid-Atlantic MIRECC, Duke Medical Center, White River Junction, VT, USA University School of Medicine, Durham, NC, USA 12 Massachusetts General Hospital, Boston, MA, USA 4 University of California, San Diego, La Jolla, CA, USA 13 5 Marinus Pharmaceuticals, Inc., Radnor, PA, USA Harvard Medical School, Boston, MA, USA 6 Zogenix, Inc., San Diego, CA, USA 14 University of Southern California, Los Angeles, CA, USA 2246 Psychopharmacology (2017) 234:2245–2257 controlled testing, and targeting of treatment to PTSD subpop- associated with anxiety-like behaviors, increased aggression, ulations with demonstrably dysregulated pre-treatment neuro- enhanced contextual fear conditioning, and extinction deficits. active steroid levels. In turn, administration of allopregnanolone, drugs that stimulate Clinicaltrials.gov identifier: NCT01339689. allopregnanolone synthesis, or an SSRI at doses well below that which block serotonin reuptake but that rectify allo- Keywords Multisite clinical trial . Ganaxolone . pregnanolone levels reverse these aberrant behaviors (Pinna Allopregnanolone . GABA receptor agonist . Neurosteroid . et al. 2006; Pibiri et al. 2008; Zhang et al. 2014). Depression . Trauma . PTSD In women with PTSD, cerebrospinal fluid (CSF) levels of allopregnanolone and pregnanolone (the GABAergic 5β stereo- isomer of allopregnanolone) were together decreased to 39% of Introduction levels seen in healthy women, correlated inversely with PTSD re-experiencing symptoms and negative mood, and were lowest Over the past 15 years, strides have been made in defining the in patients with comorbid major depressive disorder (MDD) neurobiological characteristics of PTSD (Pitman et al. 2012). (Rasmusson et al. 2006). The ratio of these GABAergic neuro- Nevertheless, there remain limited efficacious pharmacother- active steroids to the immediate allopregnanolone precursor, 5α- apies for PTSD, either as stand-alone treatment or for augmen- dihydroprogesterone, was also decreased, consistent with a tation of trauma-focused psychotherapies such as Prolonged block in their synthesis. Recent studies demonstrate a similar Exposure or Cognitive Processing Therapy (Resick et al. role for these neuroactive steroids in the pathophysiology of 2014). Medications tested in PTSD have typically shown PTSD in men (Marx 2014; Rasmusson et al. 2016). large effect sizes in small preliminary studies, but smaller Allopregnanolone acts at benzodiazepine-sensitive synap- effects when tested against placebo in large multisite trials. tic GABAA receptors and more potently at benzodiazepine- The serotonin selective reuptake inhibitors (SSRIs) sertraline insensitive, extrasynaptic GABAA receptors (Semyanov et al. and paroxetine, the only two FDA-approved medications for 2004). Of note, Chhatwal et al. (2005) demonstrated down- the treatment of PTSD, showed only moderate effect sizes in regulation of synaptic GABAA receptors in the amygdala after FDA registration trials (Brady et al. 2000; Davidson et al. fear conditioning, thus providing a rationale for the poor effi- 2001;Marshalletal.2001; Tucker et al. 2001). Combat vet- cacy in PTSD of benzodiazepines. In contrast, gabapentin and erans, in particular, appeared to be resistant to SSRIs (e.g., topiramate (which target extrasynaptic GABAA receptors) Friedman et al. 2007), although variability in outcomes across have shown efficacy in several PTSD trials (Bernardy and veteran studies now suggests that ethnicity, age, or other sub- Friedman 2015). Thus, the potential utility of population differences may play a role (Bernardy and allopregnanolone in treating PTSD appears plausible. Friedman 2015). The growing evidence for biological hetero- Although allopregnanolone has been intravenously admin- geneity underlying the PTSD phenotype has therefore pro- istered to healthy humans (Timby et al. 2006; van Broekhoven voked a call for medications that address individually variable et al. 2007), and to patients with traumatic brain injury PTSD-specific pathophysiological processes (Rasmusson and (ClinicalTrials.gov: NCT01673828), Alzheimer’sdisease Abdallah 2015; Friedman and Bernardy 2016). (ClinicalTrials.gov: NCT02221622), and postpartum depres- As discussed below, preclinical and clinical evidence sup- sion (ClinicalTrials.gov Identifier: NCT02942004), an oral ports a role for neuroactive steroids with effects at gamma- formulation of allopregnanolone is not yet available. amino-butyric acid (GABA)A receptors in the pathophysiology Ganaxolone, a synthetic 3β-methylated analog of and treatment of PTSD in at least some subpopulations. Levels allopregnanolone, can be administered orally, however. Like of allopregnanolone, a progesterone metabolite that positively allopregnanolone, ganaxolone is a positive allosteric modula- and potently modulates effects of GABA at GABAA receptors, tor of GABAA receptors and demonstrates anxiolytic and an- increase following administration of SSRIs, and appear to con- ticonvulsant actions in rodent models (Kaminski et al. 2004; tribute to the therapeutic effects of SSRIs (Uzunova et al. 1998; Reddy et al. 2004). The tolerability and safety of ganaxolone Romeo et al. 1998). In healthy humans, increases in serum also has been demonstrated in phase 1 and phase 2 clinical allopregnanolone levels during a study of the effects of preg- trials in patients with refractory epilepsy (Laxer et al. 2000; nenolone (a precursor for allopregnanolone) on emotion regu- Nohria and Giller 2007; Bialer et al. 2010). We therefore de- lation correlated negatively with amygdala activity; further, a cided to investigate ganaxolone for the treatment of PTSD in a higher ratio of allopregnanolone to pregnenolone after pregnen- phase 2, proof-of-concept clinical trial. We hypothesized that olone infusion was positively correlated with dorsomedial pre- ganaxolone would show an advantage over placebo in reduc- frontal cortex-amygdala connectivity, which in turn correlated ing PTSD symptoms and improving well-being. We also ex- negatively with anxiety (Sripada et al. 2013). In contrast, a pected ganaxolone to be well tolerated and that adverse events reduction in the corticolimbic expression of allopregnanolone would not differ between the ganaxolone and placebo in male rodent models (Pibiri et al. 2008; Zhang et al. 2014)is treatments. Psychopharmacology (2017) 234:2245–2257 2247 Methods
Loading...
Loading...
Loading...
Loading...
Loading...

8 pages remaining, click to load more.

Recommended publications
  • Exploring Matrix Effects on Binding Properties and Characterization of Cotinine Molecularly Imprinted Polymer on Paper-Based Scaffold
    Article Exploring Matrix Effects on Binding Properties and Characterization of Cotinine Molecularly Imprinted Polymer on Paper-Based Scaffold Nutcha Larpant 1, Yaneenart Suwanwong 2, Somchai Boonpangrak 3 and Wanida Laiwattanapaisal 4,5,* 1 Graduate Program in Clinical Biochemistry and Molecular Medicine, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand; Nutchalp.l@gmail.com 2 Department of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand; Yaneenart.S@chula.ac.th 3 Center for Research and Innovation, Faculty of Medical Technology, Mahidol University, Nakhon Pathom 73170, Thailand; somchai.boo@mahidol.ac.th 4 Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand 5 Electrochemistry and Optical Spectroscopy Center of Excellence, Chulalongkorn University, Bangkok 10330, Thailand * Correspondence: Wanida.L@chula.ac.th Received: 22 January 2019; Accepted: 20 March 2019; Published: 26 March 2019 Abstract: Commercially available sorbent materials for solid-phase extraction are widely used in analytical laboratories. However, non-selective binding is a major obstacle for sample analysis. To overcome this problem, molecularly imprinted polymers (MIPs) were used as selective adsorbent materials prior to determining target analysts. In this study, the use of non-covalent molecularly imprinted polymers (MIPs) for cotinine adsorption on a paper-based scaffold was studied. Fiberglass paper was used as a paper scaffold for cotinine-selective MIP adsorption with the use of 0.5% agarose gel. The effects of salt, pH, sample matrix, and solvent on the cotinine adsorption and extraction process were investigated. Under optimal conditions, the adsorption isotherm of synthesized MIPs increased to 125.41 µg/g, whereas the maximum adsorption isotherm of non-imprinted polymers (NIPs) was stable at 42.86 µg/g.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Mechanisms of Action of Antiepileptic Drugs
    Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal mkbens2@uky.edu ated with less drug–drug interactions.
    [Show full text]
  • Effect of Varenicline Combined with Medical Management on Alcohol Use Disorder with Comorbid Cigarette Smoking
    Table of Contents I. Summary of Changes to the Statistical Plan …………………. 2. II. Summary of Changes to the Protocol………………………… 2. III. Original Protocol at Trial Initiation ………………………… 5. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 I. Summary of changes to the statistical analysis plan The original statistical analysis plan is described in the original protocol below beginning on page 20. In the original statistical analysis plan the stratification factor sex was omitted unintentionally from the primary model specification for the main outcome (percent heavy drinking days, PHDD) although sex was identified as a potential moderator in an exploratory aim. At the analysis stage, we included both stratification factors (site and sex) and their interactions with treatment in the model for PHDD consistent with prior hypothesis that men and women differ in their smoking and drinking behavior and treatment response, and with good statistical practice. Baseline percent heavy drinking days was specified as a covariate in the original analysis plan but in response to comments by the statistical reviewer was dropped as a covariate and included in the final mixed model analyses reported in the paper. In order to make the baseline and end-point measures comparable, baseline percent heavy drinking days and end-point percent heavy drinking days were both summarized over 8 week periods. This 8-week duration was pre-planned for the end-point measure but modified from the original intention to use 30 days of the baseline period. Unstructured variance-covariance matrix was used for the errors since variances at baseline and end-point were different.
    [Show full text]
  • 8Th European Congress on Epileptology, Berlin, Germany, 21 – 25 September 2008
    Epilepsia, 50(Suppl. 4): 2–262, 2009 doi: 10.1111/j.1528-1167.2009.02063.x 8th ECE PROCEEDINGS 8th European Congress on Epileptology, Berlin, Germany, 21 – 25 September 2008 Sunday 21 September 2008 KV7 channels (KV7.1-5) are encoded by five genes (KCNQ1-5). They have been identified in the last 10–15 years by discovering the caus- 14:30 – 16:00 ative genes for three autosomal dominant diseases: cardiac arrhythmia Hall 1 (long QT syndrome, KCNQ1), congenital deafness (KCNQ1 and KCNQ4), benign familial neonatal seizures (BFNS, KCNQ2 and VALEANT PHARMACEUTICALS SATELLITE SYM- KCNQ3), and peripheral nerve hyperexcitability (PNH, KCNQ2). The fifth member of this gene family (KCNQ5) is not affected in a disease so POSIUM – NEURON-SPECIFIC M-CURRENT K+ CHAN- far. The phenotypic spectrum associated with KCNQ2 mutations is prob- NELS: A NEW TARGET IN MANAGING EPILEPSY ably broader than initially thought (i.e. not only BFNS), as patients with E. Perucca severe epilepsies and developmental delay, or with Rolando epilepsy University of Pavia, Italy have been described. With regard to the underlying molecular pathophys- iology, it has been shown that mutations in KCNQ2 and KCNQ3 Innovations in protein biology, coupled with genetic manipulations, have decrease the resulting K+ current thereby explaining the occurrence of defined the structure and function of many of the voltage- and ligand- epileptic seizures by membrane depolarization and increased neuronal gated ion channels, channel subunits, and receptors that are the underpin- firing. Very subtle changes restricted to subthreshold voltages are suffi- nings of neuronal hyperexcitability and epilepsy. Of the currently cient to cause BFNS which proves in a human disease model that this is available antiepileptic drugs (AEDs), no two act in the same way, but all the relevant voltage range for these channels to modulate the firing rate.
    [Show full text]
  • OPRM1 Genetic Polymorphisms Are Associated with the Plasma Nicotine Metabolite Cotinine Concentration in Methadone Maintenance Patients: a Cross Sectional Study
    Journal of Human Genetics (2013) 58, 84–90 & 2013 The Japan Society of Human Genetics All rights reserved 1434-5161/13 www.nature.com/jhg ORIGINAL ARTICLE OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study Yu-Ting Chen1, Hsiao-Hui Tsou2, Hsiang-Wei Kuo1, Chiu-Ping Fang1, Sheng-Chang Wang1, Ing-Kang Ho1,3,4, Yao-Sheng Chang1, Chia-Hui Chen1, Chin-Fu Hsiao2, Hsiao-Yu Wu2, Keh-Ming Lin1, Andrew CH Chen5, Jyy-Jih Tsai-Wu6 and Yu-Li Liu1,7,8 Majority of the heroin-dependent patients smoke cigarettes. Although it has been reported that the OPRM1 genetic polymorphism is associated with the brain mu-opioid receptor binding potential in cigarette smokers, there is no direct evidence showing the impact of plasma cotinine, a nicotine metabolite, on treatment responses to methadone maintenance treatment (MMT). In this study, we aimed to test the hypothesis that the genetic polymorphisms in the OPRM1 are associated with the methadone treatment responses and the severity of cigarette smoking directly measured by the plasma concentration of cotinine in a Taiwanese MMT cohort. Fifteen OPRM1 single-nucleotide polymorphisms (SNPs) were selected and genotyped on DNA samples of 366 MMT patients. Plasma concentrations of cotinine were measured by cotinine enzyme-linked immunosorbent assay. The plasma cotinine concentration had positive correlation with concentrations of methadone (P ¼ 0.042) and its metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (P ¼ 0.037). Methadone treatment non-responders, defined by a positive urine morphine test, had a higher plasma concentration of cotinine (P ¼ 0.005), but a lower plasma concentration-to- dose ratio of both R- and S-methadone (P ¼ 0.001 and 0.012, respectively) than the responders.
    [Show full text]
  • Nicotine Metabolism and CYP2D6 Phenotype in Smokers
    Vol. 10, 261–263, March 2001 Cancer Epidemiology, Biomarkers & Prevention 261 Short Communication Nicotine Metabolism and CYP2D6 Phenotype in Smokers Neil E. Caporaso,1 Caryn Lerman, Janet Audrain, CYP2D6 (debrisoquine hydroxylase) has been studied as a Neil R. Boyd, David Main, Haleem J. Issaq, putative lung cancer susceptibility factor, and it has been pro- Bill Utermahlan, Roni T. Falk, and Peter Shields posed that this enzyme may contribute to the metabolism of Division of Cancer Epidemiology and Genetics, National Cancer Institute, nicotine, thereby influencing the amount a person smokes and Bethesda, Maryland 20892 [N. E. C., R. T. F.]; Lombardi Cancer Research the delivery of carcinogens. Some in vitro (1) and population Center, Georgetown University, Washington, D.C. 20007 [C. L., J. A., (2) studies have suggested a role for CYP2D6 in nicotine N. R. B., D. M.]; Laboratory of Chemical Synthesis and Analysis, Frederick metabolism, although recent work indicates CYP2A6 is the Cancer Research Center, Frederick, Maryland 21701 [H. J. I., B. U.]; and Laboratory of Human Carcinogenesis, Division of Cancer Etiology, NIH, most important P-450 in nicotine metabolism (3, 4). The National Cancer Institute, Bethesda, Maryland 20892 [P. S.] CYP2D6 MP2 is determined by administering DM (5) and determining the ratio of urinary metabolites. A low ratio of unchanged drug:metabolite identifies extensive metabolizers, Abstract whereas PMs exhibit a high ratio. The hypothesis that a poly- We tested the hypothesis that the polymorphic enzyme morphic gene influences nicotine disposition is important be- CYP2D6 is related to nicotine metabolism in 261 healthy cause addicted smokers engage in smoking behavior in such a subjects enrolling in a smoking cessation clinic.
    [Show full text]
  • Escreen Panel Descriptions
    eScreen Panel Descriptions Service Description eScreen-9Panel-1205 Cocaine 300/150 Amphetamines 1000/500 Barbiturates 300/300 Ben- zodiazepines 300/300 Marijuana 50/15 Opiates 2000/2000 Phencycli- dine (PCP) 25/25 Propoxyphene 300/300 Methadone 300/300 eScreen-1065 Tramadol standalone test eScreen-10Panel-1204 Amphetamines 1000/500 Cocaine 300/150 Marijuana 50/15 Opiate 2000/2000 PCP 25/25 Barbiturate 300/300 Benzodiazepine 300/300 Propoxyphene 300/300 Methadone 300/300 Methaqualone 300/300 pH/nitrites eScreen-10Panel-3125-Other Amphetamines 500/250 Cocaine 150/100 Marijuana 50/15 Opiate 2000/2000 PCP 25/25 Barbiturate 300/300 Benzodiazepine 300/300 Methadone 300/300 Oxycodone 100/100 Ecstasy 1000/250 eScreen-1208 Amphetamines 1000/500 Cocaine 300/150 Marijuana 50/15 Opiates 2000/2000 PCP 25/25 Barbiturate 300/300 Benzodiazepine 300/300 Propoxyphene 300/300 Methadone 300/300 Methaqualone 300/300 Urine ethanol 0.04 g%/0.04 g% eScreen-1224 Amphetamines 1000/500 Cocaine 300/150 Marijuana 50/15 Opiates 2000/2000 PCP 25/25 Barbiturate 300/300 Benzodiazepine 300/300 Propoxyphene 300/300 Methadone 300/300 Methaqualone 300/300 Cotinine 500/500 pH/nitrites eScreen-1232 Amphetamines 1000/500 Cocaine 300/150 Marijuana 50/15 Opiate 2000/2000 PCP 25/25 Barbiturate 300/300 Benzodiazepine 300/300 Propoxyphene 300/300 Methadone 300/300 Methaqualone 300/300 Oxycodone 100/100 Meperidine 100/100 eScreen-1309 Amphetamines 500/250 Cocaine 150/100 Marijuana 50/15 Opiate 2000/2000 PCP 25/25 Barbiturate 300/300 Benzodiazepine 300/300 Propoxyphene 300/300 Methadone
    [Show full text]
  • Ganaxolone (Epilepsy) – Forecast and Market Analysis to 2022
    Ganaxolone (Epilepsy) – Forecast and Market Analysis to 2022 Reference Code: GDHC1071DFR Publication Date: February 2013 Executive Summary Epilepsy: Key Metrics in the Epilepsy Markets The below figure illustrates ganaxolone sales for the US 2022 Market Sales and 5EU during the forecast period. US $43.17m Sales for Ganaxolone by Region, 2022 5EU $4.64m Total $47.81m 10% 2012 Total: $47.81m Key Events (2012–2022) Level of Impact Launch of ganaxolone in the US in 2019 ↑↑↑ US Launch of ganaxolone in the 5EU in 2019 ↑↑↑ 5EU Source: GlobalData Sales for Ganaxolone in the Epilepsy Market GlobalData expects Marinus Pharmaceuticals to launch 90% ganaxolone in the US and EU in 2019. We estimate that 2022 sales of ganaxolone will reach $47.81m across Source: GlobalData these markets. Key factors affecting the uptake of ganaxolone will include: What Do the Physicians Think? Novel mechanism of action and good tolerability Overall physicians expressed a need for more AEDs profile and favorable opinions of those in pipeline Efficacy profile is not significantly different from that development. of other marketed anti-epileptic drugs (AEDs) “Among intractable epilepsy patients, any drug that helps Ganaxolone is still in early development; possible treat an additional segment of them will be used, and lack of funding to conduct Phase III trials necessary because we don’t have a basis for using one or another, for commercialization if it’s attractive, it will be used more.” [US] key opinion leader, November 2012 Heavy competition in the market “Brivaracetam is an interesting concept because it’s supposed to be “Super Keppra,” the follow-on from Keppra.
    [Show full text]
  • Chronic Smokeless Tobacco Consumption Contributes to the Development of Renal Diseases in the Human Male Volunteers
    Journal of Analytical & Pharmaceutical Research Research Article Open Access Chronic smokeless tobacco consumption contributes to the development of renal diseases in the human male volunteers Abstract Volume 7 Issue 6 - 2018 Smokeless tobacco may able to induce microalbuminuria. The present study S Fareeda Begum,1 G Nagajothi,2 K investigates the relation between nicotine and cotinine with renal function in gutkha Swarnalatha,1 C Suresh Kumar,1 Narendra and khaini users. Methods: The levels of nicotine and cotinine were estimated by HPLC 1 methods and other urine variables were detected by spectrophotometric methods. Maddu 1 Current smokeless tobacco users have shown that significantly elevated levels of Department of Biochemistry, Sri Krishnadevaraya University, India nicotine, cotinine, and epinephrine excretion in the urine than non-tobacco users. 2Department of Corporate Secretaryship, Queen Mary’s Renal function was assessed by glomerular filtration rate (GFR), levels of urea, and College (Autonomous), India creatinine. Among the kidney function measures that we examined, microalbuminuria, decreased glomerular filtration rate, and creatinine clearance were found associated Correspondence: Narendra Maddu, Assistant Professor, with gutkha and khaini users. Significantly decreased proteinuria, urea and increased Department of Biochemistry, Sri Krishnadevaraya University, levels of uric acid and creatinine excretion with the concomitant increase in plasma Ananthapuramu-515003, Andhra Pradesh, India, Tel 91+ total proteins, urea, and decreased uric acid levels were observed in the group I and 9441983797, Email group II users compared to group III users. The products of smokeless tobacco are regarded as good predictors of assessing the free radical levels in the cells. The active Received: June 01, 2018 | Published: November 26, 2018 markers of nitroxidative stress have been elevated progressively with the uptake of nicotine and exposure.
    [Show full text]
  • Molecular Mechanisms of Antiseizure Drug Activity at GABAA Receptors
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Seizure 22 (2013) 589–600 Contents lists available at SciVerse ScienceDirect Seizure jou rnal homepage: www.elsevier.com/locate/yseiz Review Molecular mechanisms of antiseizure drug activity at GABAA receptors L. John Greenfield Jr.* Dept. of Neurology, University of Arkansas for Medical Sciences, 4301W. Markham St., Slot 500, Little Rock, AR 72205, United States A R T I C L E I N F O A B S T R A C T Article history: The GABAA receptor (GABAAR) is a major target of antiseizure drugs (ASDs). A variety of agents that act at Received 6 February 2013 GABAARs s are used to terminate or prevent seizures. Many act at distinct receptor sites determined by Received in revised form 16 April 2013 the subunit composition of the holoreceptor. For the benzodiazepines, barbiturates, and loreclezole, Accepted 17 April 2013 actions at the GABAAR are the primary or only known mechanism of antiseizure action. For topiramate, felbamate, retigabine, losigamone and stiripentol, GABAAR modulation is one of several possible Keywords: antiseizure mechanisms. Allopregnanolone, a progesterone metabolite that enhances GABAAR function, Inhibition led to the development of ganaxolone. Other agents modulate GABAergic ‘‘tone’’ by regulating the Epilepsy synthesis, transport or breakdown of GABA. GABAAR efficacy is also affected by the transmembrane Antiepileptic drugs chloride gradient, which changes during development and in chronic epilepsy. This may provide an GABA receptor Seizures additional target for ‘‘GABAergic’’ ASDs. GABAAR subunit changes occur both acutely during status Chloride channel epilepticus and in chronic epilepsy, which alter both intrinsic GABAAR function and the response to GABAAR-acting ASDs.
    [Show full text]
  • Ketamine Homogeneous Enzyme Immunoassay (HEIA™)
    Ketamine Homogeneous Enzyme Immunoassay (HEIA™) Exclusively from Immunalysis Formula: C13H16CINO Semi-Quantitative or Qualitative Testing Systematic Name: (RS)- 2- (2- chlorophenyl)- 2- (methylamino)cyclohexanone Accurate and reliable Brand Names: Ketanest®, Ketaset®, Ketalar® Ready to use About Ketamine: Ketamine is an anesthetic agent used in the United States since 1972 for veterinary and pediatric medicine. It is also used in the treatment of depression and postoperative pain management. However, in recent years it has gained popularity as a street drug used at clubs and raves due to its hallucinogenic effects. Administration: Oral; intravenous; intramuscular; insufflation Elimination: Ketamine metabolizes by N-demethylation to Norketamine and further dehydrogenates to Dehydronorketamine. After 72 hours of a single dose, 2.3% of Ketamine is unchanged, 1.6% is Norketamine, 16.2% is Dehydronorketamine, and 80% is hydroxylated derivatives of Ketamine.1,2 Abuse Potential: An overdose can cause unconsciousness and dangerously slowed breathing. 1) R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, Fourth Edition, p. 412-414. 2) K. Moore, J.Skerov, B.Levine, and A.Jacobs, Urine Concentrations of Ketamine and Norketamine Following Illegal Consumption, J.Anal, Toxicol. 25: 583-588 (2001). Ketanest® is a registered trademark of Pfizer, Inc., Ketaset® is a trademark of ZOETIS W LLC., Ketalar® is a trademark of PAR STERILE PRODUCTS, LLC. Tel 909.482.0840 | Toll Free 888.664.8378 | Fax 909.482.0850 ISO13485:2003 www.immunalysis.com CERTIFIED
    [Show full text]